Flash Therapeutics

What Flash Therapeutics does

Flash Therapeutics, now operating under the Flash BioSolutions brand since March 2024, is a France-based Contract Development and Manufacturing Organisation (CDMO) headquartered in Toulouse that specialises in lentiviral vector manufacturing for gene and cell therapy applications. The company's technology stack rests on two proprietary platforms: DNA-based lentiviral vectors for stable, long-term transgene expression, and the FlashRNA® (LentiFlash®) non-integrative viral RNA delivery system, which uses a bacteriophage-driven RNA packaging architecture with Coat-retrovirus chimeras to enable transient, efficient, and safe gene expression. Both platforms are protected by patents filed from 2011 onward and by registered trademarks (LentiFlash®, FlashRNA®), and are supported by cGMP-compliant manufacturing infrastructure (first GMP batch produced in 2019).

The company monetises these platforms through a B2B services-plus-products model: research-grade and GMP-grade custom lentiviral vector manufacturing (R&D Manufacturing Offer, GMP Manufacturing Offer, GMP Flash Track accelerated pathway, and Flash & Finish fill-finish services), complemented by off-the-shelf Premade Lentiviral Vectors distributed worldwide through Takara Bio / Clontech. Revenue is generated via quote-based custom manufacturing contracts with pharmaceutical and biotechnology clients, while partnered therapeutic programs (TheraLymph for regenerative medicine, IRIS for cell therapy targeting inherited immune disorders, and R&D & Innovation collaborations) extend the model into co-development arrangements.

Flash Therapeutics serves enterprise pharmaceutical companies, biotechnology companies developing advanced therapies (CAR-T, gene editing, immunotherapy), and academic/research institutions. Go-to-market is enterprise field sales with direct engagement and a "Request a quote" workflow. The customer base includes tier-1 pharma (Sanofi, Roche) and research institutes (Gustave Roussy, University of Zurich, Evotec, SmartImmune, KiraGen Bio), with operating geographies spanning Europe and North America. The company employs 11-50 people and has raised approximately €20M cumulatively since inception, anchored by a €15M financing agreement with TechLife Capital and Elaia Partners in 2021 alongside French government and Occitanie Region grants. Leadership includes CEO and founder Pascale Bouillé and President of the Supervisory Board Jacques Rossignol, with Anne Deflisque (Business & Marketing Director, April 2024) and Stewart Craig (Scientific Advisory Board, April 2024) joining recently to support commercial scale-up.

Name

Flash Therapeutics

Website

https://flashtherapeutics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Flash Therapeutics (rebranded Flash BioSolutions in 2024) is a French CDMO based in Toulouse that manufactures proprietary lentiviral vectors for gene and cell therapy, serving pharmaceutical and biotechnology companies from R&D through GMP-grade production.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)

akta.pro secondary industries

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Lentiviral Vector Gene Therapy Developers (HLAAACAB), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)

Keywords

• Lentiviral vector manufacturing
• Gene therapy CDMO
• Viral vector production
• RNA delivery technology
• Biopharmaceutical contract manufacturing

Headquarters

HQ city

Toulouse

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services: Contract Development and Manufacturing Organization providing lentiviral vector manufacturing services from R&D grade to GMP clinical grade. Services include R&D Manufacturing offer, GMP Manufacturing offer, GMP Flash Track, and Flash & Finish services. Revenue generated through service contracts with pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Flash Therapeutics is a Contract Development and Manufacturing Organization (CDMO) specialized in lentiviral vector manufacturing for gene and cell therapy. The company delivers a full continuum of services from R&D-grade to GMP clinical-grade production using two proprietary platforms: Lentiviral Vectors for stable DNA-based gene expression and FlashRNA® (LentiFlash®) for non-integrative, transient RNA delivery. Offerings include custom and premade lentiviral vectors, R&D and GMP manufacturing, accelerated GMP Flash Track, and fill-finish services for pharmaceutical and biotech clients.

Product overview

Flash Therapeutics (now Flash BioSolutions) is a Contract Development and Manufacturing Organisation (CDMO) expert in lentiviral vector manufacturing, offering a continuum from research to the clinic. Its product portfolio centers on two proprietary technology platforms: Lentiviral Vectors for stable, long-term DNA-based gene expression, and FlashRNA® (LentiFlash®) for non-integrative, transient RNA delivery. These platforms are supported by manufacturing services ranging from R&D grade to GMP clinical grade, including accelerated GMP Flash Track and fill-finish capabilities. The company also distributes standard Premade Lentiviral Vectors and offers Custom Lentiviral Vectors. In parallel, Flash Therapeutics advances partnered therapeutic programs (TheraLymph for regenerative medicine, IRIS for cell therapy targeting inherited immune disorders) and R&D & Innovation programs, reflecting its integrated CDMO-plus-therapeutics business model.

Differentiator

Problem solved

Functional benefit

Products and services

• Lentiviral Vectors

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• SanoficoreStrategic or Co-development PartnerMajor pharmaceutical partner with long-term collaboration. Flash Therapeutics has been working with Sanofi for several years with successful outcomes.
• Roche / Hoffmann-La RochecoreStrategic or Co-development PartnerStrategic partnership with major pharmaceutical company for lentiviral vector manufacturing and gene therapy development.
• Gustave RoussycoreStrategic or Co-development PartnerPartnership with leading cancer research institute for immunotherapy and cell therapy development using lentiviral vectors.
• EvoteccoreStrategic or Co-development PartnerStrategic partnership with life sciences company for gene therapy and lentiviral vector development.
• University of ZurichcoreStrategic or Co-development PartnerAcademic partnership with leading Swiss university for research and development of gene therapy applications.
• SmartImmunecoreStrategic or Co-development PartnerPartnership with biotech company focused on immune therapies and lentiviral vector applications.
• Shift BiominorStrategic or Co-development PartnerPartnership with South Korean biotech company for gene therapy development.
• KiraGen BiocoreStrategic or Co-development PartnerInnovative partnership announced April 2024 to revolutionize CAR-T therapies for solid tumors using combined expertise in lentiviral vector manufacturing.
• Takara Bio / ClontechcoreChannel Partner/ Reseller/ DistributorDistribution partnership since 2014 for standard product offers distributed worldwide through Clontech and Takara Bio network.
• Institut PasteurminorStrategic or Co-development PartnerPartnership with renowned French research institution for gene therapy and viral vector development.
• CNRSminorStrategic or Co-development PartnerPartnership with French National Centre for Scientific Research for R&D programs.
• InsermminorStrategic or Co-development PartnerPartnership with French National Institute of Health and Medical Research for Theralymph program.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Oxford BioMedica: UK-based lentiviral vector specialist CDMO with proprietary LentiVector platform and GMP manufacturing. Directly comparable to Flash BioSolutions on lentiviral focus, GMP capabilities, and pharma/biotech customer base.
• Yposkesi (SK Pharmteco): French viral vector CDMO specializing in AAV and lentiviral GMP manufacturing for gene therapy. Comparable on viral vector CDMO services and European geographic footprint.
• Vibalogics: German-based CDMO focused on lentiviral vectors and viral vaccines with GMP manufacturing capacity. Directly comparable on lentiviral specialization and clinical-to-commercial batch manufacturing.
• Cobra Biologics (Charles River Laboratories): Viral vector and plasmid DNA CDMO within Charles River, offering lentiviral and AAV GMP manufacturing. Comparable on viral vector CDMO services to gene therapy and cell therapy developers.

Emerging players

• Genezen: US-based lentiviral and AAV gene therapy CDMO with early-to-clinical GMP manufacturing. Comparable as a focused viral vector CDMO targeting gene and cell therapy developers.
• VectorBuilder: Global provider of custom viral vectors (lentiviral, AAV, adenoviral) for research and preclinical use, increasingly expanding into GMP. Comparable on lentiviral vector technology and serving similar biotech/research customers.

Broad incumbents

• AGC Biologics: Global CDMO offering viral vector (AAV and lentiviral) manufacturing alongside biologics. Overlaps with Flash BioSolutions on lentiviral CDMO services but operates at broader scale and modality mix.
• Lonza: Largest global CDMO with significant viral vector and cell & gene therapy manufacturing capacity. Competes for the same pharma CDMO contracts but offers substantially broader services and global footprint.
• Catalent: Major CDMO with viral vector and cell therapy manufacturing services, including lentiviral capabilities. Comparable end-market (gene therapy sponsors) but operates at meaningfully larger scale.
• Aldevron: Provides plasmid DNA, mRNA, and viral vector manufacturing services for gene therapy and vaccine developers. Overlaps with Flash BioSolutions on serving gene therapy CDMO demand with broader nucleic acid capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/FlashTherapeutx
• YouTubeyoutube.com/channel/UCCM6KC1ACTBveNVYpBnnwtg
• LinkedInlinkedin.com/company/flashtherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flash Therapeutics